WS
PTCT icon

Wedbush Securities’s PTC Therapeutics PTCT Stock Holding History

Wedbush Securities’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,500
Closed -$68K – 819
2016
Q1 		$68K Buy
+10,500
New +$182K 0.01% 682

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wedbush Securities's PTCT Position: Q2 2016 in Review

Wedbush Securities sold out of PTC Therapeutics (PTCT) in Q2 2016, closing a stake of 10,500 shares — an estimated $68K sold.

Wedbush Securities first reported a position in PTCT in Q1 2016 and held it in 1 quarter. The position peaked at $68K in Q1 2016. 118 funds tracked by Wall St. Rank hold PTCT as of Q2 2016.

  • Wedbush Securities reported no remaining PTC Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Wedbush Securities sold 10,500 PTC Therapeutics shares in Q2 2016, an estimated $68K.
  • Wedbush Securities first reported a position in PTC Therapeutics in Q1 2016 and held it in 1 quarter.
  • Wedbush Securities's PTC Therapeutics position peaked at $68K in Q1 2016.
  • 118 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2016.

Based on Wedbush Securities's 13F filing for Q2 2016, filed 2 Aug 2016.